Novartis gains European Commission approval for Lucentis® to treat vision loss due to macular edema secondary to RVO
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO and central RVO), a sudden-onset disease where patients have difficulties with daily activities such as reading, cooking and driving.
- (1888PressRelease) June 06, 2011 - Lucentis becomes the first anti-VEGF therapy licensed for the treatment of both branch- and central-RVO in the European Union, having demonstrated in pivotal trials that it improves vision and vision-related quality of life for these patients.
Lucentis (ranibizumab) is first anti-VEGF approved for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO)
Pivotal clinical data show rapid and significant improvements in visual acuity at six months with Lucentis treatment compared with standard of care (P
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam